Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS 41004 concentration-ranging psoriasis plaque test
2011-000186-13Phase 2Completed
- Sponsor
- Almirall
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of LAS41004 IMP5, bexarotene, betamethasone dipropionate, tazarotene and calcipotriol + betamethasone in plaque psoriasis (8 arms), sponsored by Almirall. Primary endpoint: AUC of echo-lucent band width. Started Feb 2011; status: completed.
02
Drugs
LAS41004 IMP5bexarotenebetamethasone dipropionatetazarotenecalcipotriol + betamethasone
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2011-000186-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000186-13.